Cipher Pharmaceuticals (CPH) Aperçu de l'action
Cipher Pharmaceuticals Inc. est une société pharmaceutique spécialisée au Canada. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 6/6 |
| Croissance future | 1/6 |
| Performances passées | 6/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour CPH à partir de nos contrôles de risques.
CPH Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cipher Pharmaceuticals Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | CA$16.92 |
| Plus haut sur 52 semaines | CA$20.56 |
| Plus bas sur 52 semaines | CA$11.87 |
| Bêta | 0.49 |
| Variation sur 1 mois | -8.49% |
| Variation sur 3 mois | 16.13% |
| Variation sur 1 an | 39.83% |
| Variation sur 3 ans | 364.84% |
| Variation sur 5 ans | 1,135.04% |
| Évolution depuis l'introduction en bourse | 357.30% |
Nouvelles et mises à jour récentes
Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings
Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...
CPH: Higher Cash Returns And Buybacks Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These changes support a slightly higher fair value estimate.Recent updates
Investors Shouldn't Be Too Comfortable With Cipher Pharmaceuticals' (TSE:CPH) Earnings
Cipher Pharmaceuticals Inc. ( TSE:CPH ) announced strong profits, but the stock was stagnant. Our analysis suggests...CPH: Higher Cash Returns And Buybacks Will Support Future Upside
Analysts have lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E. These changes support a slightly higher fair value estimate.CPH: Higher Cash Flow Plans And Buybacks Will Support Future Upside
Analysts have nudged their fair value estimate for Cipher Pharmaceuticals to CA$21 from CA$20, tying the CA$1 price target change to updated assumptions around revenue growth, profit margins and a slightly higher discount rate alongside a lower future P/E. Analyst Commentary Recent research points to a modestly higher fair value for Cipher Pharmaceuticals, with bullish analysts lifting their price target to CA$21 from CA$20.
CPH: Fair Outlook Will Weigh Natroba Expansion And Acquisition Execution
Analysts have nudged their price target on Cipher Pharmaceuticals up to CA$21 from CA$20, citing updated assumptions that keep fair value broadly steady while fine tuning expectations around growth, margins, and P/E levels. Analyst Commentary The latest price target move to CA$21 from CA$20 signals only a modest reset in expectations, rather than a major shift in conviction.CPH: Balanced Outlook Will Weigh New Drug Review And Acquisition Execution
Analysts recently lifted their price target on Cipher Pharmaceuticals to CA$21 from CA$20, reflecting updated assumptions that combine a higher revenue growth outlook with slightly lower profit margin and future P/E expectations. Analyst Commentary The latest price target move to CA$21 suggests that covering analysts are refining their assumptions rather than making a sweeping change in their outlook.CPH: New Drug Review Will Support Future Upside Potential
Analysts are maintaining their CA$18.60 price target on Cipher Pharmaceuticals. This reflects only small adjustments to their revenue growth and future P/E assumptions, rather than a change in their overall view of the stock.CPH: New Drug Review And Strong Margins Will Support Further Upside
Analysts kept their CA$18.60 price target on Cipher Pharmaceuticals unchanged, citing only small tweaks to their revenue growth, profit margin and future P/E assumptions that did not materially shift their view of the stock’s value. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad) for the treatment of head lice and scabies, moving the product into the formal review process (Key Developments).CPH: Higher Margins And New Submission Will Support Future Upside
Analysts have trimmed their price target on Cipher Pharmaceuticals to reflect a more muted revenue growth outlook of 4.30% and a slightly higher discount rate of 6.25%, while still acknowledging a stronger projected profit margin of 39.46% and a broadly similar future P/E of 17.63. What's in the News Health Canada accepted Cipher Pharmaceuticals' new drug submission for Natroba (Spinosad), targeting head lice and scabies in the Canadian market (Key Developments).CPH: Share Repurchases Will Drive Future Earnings Power And Upside Potential
Analysts have modestly adjusted their price target for Cipher Pharmaceuticals to reflect slightly updated assumptions around revenue growth of 10.48%, profit margin of 32.39%, and a future P/E of 17.81x. The overall fair value estimate remains at $18.60.CPH: Share Repurchases Will Support Stronger Future Earnings Profile
Analysts have trimmed their price target on Cipher Pharmaceuticals by aligning slightly lower revenue growth and profit margin assumptions with a modestly higher future P/E. This keeps fair value around $18.60 and reflects a more measured outlook on the company’s earnings profile.CPH: Share Repurchases And Rising Margins Will Support Stronger Future Earnings
Cipher Pharmaceuticals' analyst price target has been raised from 14.50 dollars to 18.60 dollars, as analysts cite slightly stronger expected revenue growth, modestly higher profit margins, and a richer future earnings multiple as justification for the upward revision. What's in the News Cipher Pharmaceuticals completed the latest tranche of its share repurchase program between July 1, 2025 and September 30, 2025, buying back 141,700 shares, or 0.56 percent of its float, for CAD 2.18 million (Key Developments) Under the buyback announced on May 1, 2025, the company has now repurchased a total of 371,978 shares, representing 1.46 percent of shares outstanding, for aggregate consideration of CAD 5.12 million (Key Developments) Valuation Changes The consensus analyst price target has risen significantly from 14.50 dollars to 18.60 dollars, reflecting a materially higher fair value assessment.CPH: Share Buybacks Will Support Earnings And Maintain A Balanced Outlook
Analysts have nudged their price target on Cipher Pharmaceuticals higher, from 14.00 dollars to 14.50 dollars, citing stronger expected revenue growth, improved profit margins, and a more attractive forward earnings multiple despite a slightly higher discount rate. What's in the News Cipher Pharmaceuticals repurchased 141,700 shares between July 1 and September 30, 2025, totaling CAD 2.18 million and representing 0.56% of outstanding shares (company buyback update).Cipher Pharmaceuticals Inc. (TSE:CPH) Analysts Are Pretty Bullish On The Stock After Recent Results
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...These 4 Measures Indicate That Cipher Pharmaceuticals (TSE:CPH) Is Using Debt Extensively
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Expansion Into Canada Will Shape Global Dermatology Success
Cipher Pharmaceuticals' future P/E has risen sharply, indicating increased valuation relative to earnings, while the net profit margin is stable, resulting in no change to the consensus analyst price target at CA$17.90. What's in the News Cipher Pharmaceuticals is actively seeking accretive acquisitions and in-licensing opportunities, with a strategic focus on complementary U.S.-based assets and companies.Cipher Pharmaceuticals Inc.'s (TSE:CPH) Shares Climb 27% But Its Business Is Yet to Catch Up
The Cipher Pharmaceuticals Inc. ( TSE:CPH ) share price has done very well over the last month, posting an excellent...We Think That There Are More Issues For Cipher Pharmaceuticals (TSE:CPH) Than Just Sluggish Earnings
Investors weren't pleased with the recent soft earnings report from Cipher Pharmaceuticals Inc. ( TSE:CPH ). Our...Cipher Pharmaceuticals Inc. (TSE:CPH) Stocks Shoot Up 29% But Its P/E Still Looks Reasonable
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have had a really impressive month, gaining 29% after a shaky period...Is Cipher Pharmaceuticals (TSE:CPH) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Acquisition Of Natroba And Pipeline Products Will Strengthen Future Market Presence
Strategic acquisitions and transitioning to an in-house sales team are aimed at reducing costs and boosting revenue and earnings for Cipher Pharmaceuticals.We Think Cipher Pharmaceuticals (TSE:CPH) Is Taking Some Risk With Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Cipher Pharmaceuticals' (TSE:CPH) Anemic Earnings Might Be Worse Than You Think
Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) earnings announcement last week contained some soft numbers, disappointing...With A 29% Price Drop For Cipher Pharmaceuticals Inc. (TSE:CPH) You'll Still Get What You Pay For
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders won't be pleased to see that the share price has had a very rough...Cipher Pharmaceuticals Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shareholders are probably feeling a little disappointed, since its shares fell...There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise
Cipher Pharmaceuticals Inc. ( TSE:CPH ) shares have continued their recent momentum with a 26% gain in the last month...Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)
The market rallied behind Cipher Pharmaceuticals Inc.'s ( TSE:CPH ) stock, leading do a rise in the share price after...Rendement pour les actionnaires
| CPH | CA Pharmaceuticals | CA Marché | |
|---|---|---|---|
| 7D | -5.8% | -6.3% | -0.2% |
| 1Y | 39.8% | 44.6% | 32.6% |
Rendement vs Industrie: CPH a dépassé le secteur Canadian Pharmaceuticals qui a rapporté 44.6 % au cours de l'année écoulée.
Rendement vs marché: CPH a dépassé le marché Canadian qui a rapporté 32.6 % au cours de l'année écoulée.
Volatilité des prix
| CPH volatility | |
|---|---|
| CPH Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 11.2% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.9% |
Cours de l'action stable: CPH n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Canadian.
Volatilité au fil du temps: La volatilité hebdomadaire de CPH ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2000 | n/a | Craig Mull | www.cipherpharma.com |
Cipher Pharmaceuticals Inc. est une société pharmaceutique spécialisée au Canada. Elle propose Epuris (isotrétinoïne), un rétinoïde oral indiqué pour le traitement de l'acné nodulaire et/ou inflammatoire sévère, de l'acné conglobée et de l'acné récalcitrante ; Actikerall, une solution topique indiquée pour le traitement de la kératose actinique hyperkératosique légèrement palpable et/ou modérément épaisse (grade I/II) du visage, du front et du cuir chevelu dégarni ; Natroba pour le traitement topique des infestations par les poux de tête et la gale chez les patients adultes et pédiatriques ; Vaniqa, une crème topique pour le ralentissement de la croissance des poils indésirables du visage chez les femmes ; Durela, un analgésique opioïde pour la gestion de la douleur modérée à modérément sévère chez les adultes ; Brinavess pour la conversion rapide de la fibrillation auriculaire en rythme sinusal chez les adultes ; et Aggrastat, un inhibiteur réversible de la GP IIb/IIIa à utiliser chez les patients souffrant du syndrome coronarien aigu. Les produits sous licence de la société comprennent Absorica, un rétinoïde oral indiqué pour le traitement de l'acné nodulaire et/ou inflammatoire sévère, de l'acné conglobée et de l'acné récalcitrante ; Lipofen, qui est indiqué comme traitement d'appoint au régime alimentaire pour réduire les taux élevés de LDL-C, de C total, de triglycérides et d'Apo B, et pour augmenter le HDL-C, ainsi que pour réduire les triglycérides chez les patients adultes ; et Conzip, un agoniste opioïde indiqué pour la gestion de la douleur chronique modérée à modérément sévère chez les adultes.
Cipher Pharmaceuticals Inc. Résumé des fondamentaux
| CPH statistiques fondamentales | |
|---|---|
| Capitalisation boursière | CA$431.14m |
| Bénéfices(TTM) | CA$42.42m |
| Recettes(TTM) | CA$70.00m |
Le site CPH est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CPH compte de résultat (TTM) | |
|---|---|
| Recettes | US$50.94m |
| Coût des recettes | US$9.36m |
| Marge brute | US$41.58m |
| Autres dépenses | US$10.71m |
| Les revenus | US$30.87m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 1.22 |
| Marge brute | 81.63% |
| Marge bénéficiaire nette | 60.60% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de CPH?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 07:27 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Cipher Pharmaceuticals Inc. est couverte par 8 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Novak | ATB Cormark Historical (Cormark Securities) |
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Prakash Gowd | CIBC Capital Markets |